Groundbreaking Lupus Diagnostic and Monitoring Technology Developed at Lahey Clinic

[Guest guest]

September 05, 2006 08:15 AM US Eastern Timezone

Groundbreaking Lupus Diagnostic and Monitoring Technology Developed

at Lahey Clinic Now Available Through Competitive Technologies

FAIRFIELD, Conn.--(BUSINESS WIRE)--Sept. 5, 2006--Competitive

Technologies, Inc. (AMEX:CTT) today announced that it has signed an

exclusive, worldwide service and representation agreement with Dr.

Agnello of Lahey Clinic to commercialize a patented

laboratory test used to diagnose and monitor Systemic Lupus

Erythematosus ( " SLE " ).

SLE, commonly called " Lupus, " is an autoimmune disease characterized

by the appearance in serum of antibodies directed against a number of

" self " antigens. Lupus currently affects approximately 1.5 million

patients in the United States.

" We believe that a significant market exists for better Lupus

diagnostic and monitoring tools, " commented Aris Despo, Senior Vice

President, Life Sciences for Competitive Technologies. " The Agnello

technology is a late stage technology that is ready for

commercialization and provides a cost effective, scalable testing

platform for the early detection of Lupus as well as the monitoring

of therapeutic efficacy and flares. "

The solid-phase assay significantly improves the detection of

antibodies specifically directed towards dsDNA in serum with

unparalleled sensitivity and precision compared to existing

diagnostic methods that detect and have difficulty separating both

ssDNA and dsDNA. The assay is adaptable to operate on commercially

available chemiluminescence detection platforms and has extensive

clinical data with more than 10,000 assays performed at the Lahey

Clinic.

" It will be extremely gratifying to see the fruits of our research

efforts reach the general public, " remarked Dr. Agnello. " Bringing

this technology to market through CTT's licensing network will

benefit patients around the world. I am delighted to play a role in

advancing Lahey Clinic's unique model of medicine that constantly

works at improving patient care through cutting edge research and

development. "

" This Lupus diagnostic technology is a strong addition to our life

sciences offering, " added D.J. Freed, Ph.D., President and Chief

Executive Officer of Competitive Technologies. " As we aggressively

expand our portfolio of available technologies, we are pleased to

acquire the rights to commercialize late stage technologies with

proven efficacy like this Lupus test. We are excited about bringing

this technology to the market on a global scale by leveraging our

existing relationships with diagnostic kit manufacturers who have

licensed other diagnostic assays from CTT. "

About Lahey Clinic

Lahey Clinic, a physician-led, nonprofit group practice, is world-

renowned for innovative technology, pioneering medical treatment, and

leading-edge research. A teaching hospital affiliated with Tufts

University School of Medicine, the Clinic provides quality health

care in virtually every specialty and subspecialty, from primary care

to cancer diagnosis and treatment to kidney and liver

transplantation. For more information, please visit : www.lahey.org

http://home.businesswire.com/portal/site/google/index.jsp?

ndmViewId=news_view & newsId=20060905005428 & newsLang=en